New Paradigm for Genetically Defined Neurodegeneration

CNS-Directed Gene Therapies for Neurodegenerative Diseases

Jaya Biosciences is a privately held pre-clinical stage life sciences company developing therapies for genetically defined neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and frontotemporal dementia.

neurodegeneration, Alzheimer

Our Lead Therapy

JB111 is an experimental CNS-directed AAV9-mediated PPT1 gene therapy currently being developed for neurodegeneration associated with PPT1 haploinsufficiency (carrier status for loss-of-function mutations in palmitoyl protein thioesterase-1 gene or PPT1 heterozygosity).

Latest News

Featured
Jaya Biosciences Has Been Selected for the Inaugural SCbioDrive Cohort of Highly Promising Oncology and Neuroscience Startups

This program will support our efforts to advance groundbreaking innovations in neurodegeneration alongside other exceptional early-stage companies.

Read More →
Jaya Biosciences Presents Updated Preclinical Data in Alzheimer’s Disease at the 45th SIMD Annual Meeting

Study results confirm potential utility of targeting lysosomal genes to treat neurodegenerative diseases, including Alzheimer’s disease

Read More →
Jaya Biosciences Presents New Paradigm for the Treatment of Alzheimer’s Disease at the 23rd Annual Needham Virtual Healthcare Conference

Data presented highlight the potential utility of targeting lysosomal genes to treat neurodegenerative diseases, including Alzheimer’s

Read More →